SamanTree Medical Secures $20M Series B to Revolutionize Intraoperative Cancer Surgery with the Histolog® Scanner

SamanTree Medical SA is thrilled to announce a major funding milestone, having successfully raised €20,000,000 to accelerate the evolution of its innovative Histolog® Scanner. Founded in December 2014 as a spin-off from the esteemed EPFL (École Polytechnique Fédérale de Lausanne), SamanTree Medical has quickly carved a niche at the intersection of medical technology and surgical precision by developing breakthrough imaging modalities designed for real-time cancer surgery. The Histolog® Scanner represents a paradigm shift in the operating room by allowing surgeons to verify complete tumor removal with histological accuracy during procedures. This revolutionary approach not only augments surgical margin assessments but also significantly lowers the risk of re-operations, thus directly contributing to improved patient outcomes and enhanced quality of life. The newly secured funding will play a pivotal role in scaling up clinical trials, further refining the imaging technology, and expanding the team’s research and development capabilities. SamanTree Medical SA remains dedicated to its mission of establishing the gold standard for intra-operative margin assessment, ensuring that every patient receives maximum care and precision during surgery. With this financial boost, the company is well-positioned to transform routine surgical practices, reducing the physical and emotional burdens associated with cancer surgeries. As the healthcare landscape continues to evolve, SamanTree Medical SA is at the forefront of integrating advanced technology with patient-centered care, and this funding represents a significant leap toward a future where real-time, detailed imaging in the operating room is a standard, ultimately reshaping surgical oncology practices for the better. For more information, visit linktr.ee/SamanTree.